RA
Ronald Asbury Andrews
Former CEODirector

Ronald Asbury Andrews insider trades: Oncocyte (OCX) stock purchases

Former CEO, Oncocyte Last trade Aug 16, 2022 63 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2005
8
Companies
last trade 2022

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Ronald reports to the SEC

and 2 more companies

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 16, 2022OCX↑ Buy$38K
Mar 16, 2022OCX↑ Buy$64K
Mar 19, 2021OCX↑ Buy$53K
Aug 3, 2020OCX↑ Buy$54K
Mar 30, 2020OCX↑ Buy$61K
Apr 27, 2012LIFE↑ Buy$155K
Mar 12, 2010CLRT↑ Buy$29K
Sep 18, 2008CLRT↑ Buy$15K
May 7, 2007CLRT↑ Buy$10K
Nov 14, 2005CLRT↑ Buy$12K
Jun 10, 2005CLRT↑ Buy$25K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Ronald Asbury Andrews's insider trades

Ronald Asbury Andrews is Former CEO at Oncocyte (OCX). Since Jun 10, 2005, Ronald has reported 11 open-market purchases worth $516K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (37 filings), option exercises (8 filings), shares returned to the company (7 filings), shares withheld for taxes (4 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OCX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.